Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 31 points (0.2%) at 16,096 as of Monday, Nov. 25, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,434 issues advancing vs. 1,496 declining with 119 unchanged. The Drugs industry currently sits up 1.1% versus the S&P 500, which is up 0.1%. Top gainers within the industry include Cubist Pharmaceuticals ( CBST), up 8.5%, Biogen Idec ( BIIB), up 4.2%, Vertex Pharmaceuticals ( VRTX), up 3.1%, Amgen ( AMGN), up 0.7% and Eli Lilly and Company ( LLY), up 0.6%. TheStreet would like to highlight 5 stocks pushing the industry higher today: 5. Celgene Corporation ( CELG) is one of the companies pushing the Drugs industry higher today. As of noon trading, Celgene Corporation is up $2.05 (1.2%) to $165.38 on average volume. Thus far, 1.4 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $163.44-$165.74 after having opened the day at $164.73 as compared to the previous trading day's close of $163.33. Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $65.4 billion and is part of the health care sector. The company has a P/E ratio of 45.6, above the S&P 500 P/E ratio of 17.7. Shares are up 102.1% year to date as of the close of trading on Friday. Currently there are 20 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.